2024 Cisplatin versus carboplatin

Cisplatin versus carboplatin

Author: zgyk

August undefined, 2024

WebAdvanced NSCL patients treated with carboplatin or cisplatin doublet with third-generation chemotherapy drugs showed equivalent overall survival, one-year survival, and response rate. Regarding adverse events, carboplatin caused more thrombocytopenia, and cisplatin caused more nausea/vomiting. WebSep 12, 2024 · Though cisplatin and carboplatin have similar properties and structures, the body eliminates them differently. The kidneys eliminate up to 40% of cisplatin within …

Cisplatin vs. carboplatin-based chemoradiotherapy in patients ... - PubMed

WebFeb 19, 2009 · Cisplatin carries a higher toxicity profile, including nausea, vomiting, neuropathy, renal insufficiency, and alopecia in comparison to carboplatin. When the … WebApr 4, 2024 · Balancing factors were planned platinum agent (cisplatin vs carboplatin), preoperative radiologically or pathologically assessed nodal involvement (N0 vs N1 vs N2 vs N3), status of microscopic surgical margins (positive vs negative), and treating centre. Participants were randomly allocated (1:1) either surveillance or chemotherapy. jl hudson\\u0027s cookbook

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus ...

WebThe platinum-based drugs cisplatin, carboplatin and oxaliplatin are regularly prescribed in the treatment of cancer and while they are effective, their use is limited by their severe, dose-limiting side effects (also referred to as adverse effects/events). In total, a cancer patient can experience any combination of around 40 specific side effects. WebDec 7, 2024 · Therefore, carboplatin has been indicated as a reasonable substitute for cisplatin in ES-SCLC [ 7 ]. Recently, a meta-analysis of 663 individual patient data from … WebAug 12, 2024 · Furthermore, although no outcome differences were observed between pediatric and adolescent patients treated with carboplatin- versus cisplatin-based regimens after controlling for other known risk factors, only 43 AYA patients (5%) treated with carboplatin-based regimens were included in this analysis. instatistc

Cisplatin versus carboplatin in NSCLC: is there one "best" …

The use of cisplatin in patients after kidney... : Medicine

WebChemotherapy protocol: The TP chemotherapy regimen used was paclitaxel liposome 135 mg/m 2 d1 plus cisplatin 25 mg/m 2 d1‐3 every 3 weeks. The PF group was 5‐FU 600 mg/m 2 d1‐3 and cisplatin 25 mg/m 2 d1‐3 every 4 weeks. Chemotherapy was simultaneously supplemented with antiemetic, anti‐allergy, and other symptomatic … WebApr 10, 2024 · We stratified the study participants according to 4 factors: 1) primary disease site (oral cavity/oropharynx vs. non-oral cavity/oropharynx), 2) treatment modality (post-operative or definite CCRT), 3) treatment schedule (weekly vs. 3-week), and 4) chemotherapy regimen (cisplatin vs. carboplatin). instating meaning in hindiWebWe investigated the activity and safety of first-line GEMOX compared with gemcitabine–carboplatin (GCb) in cisplatin-ineligible patients with advanced UCC. Methods: Treatment-naive, cisplatin-ineligible patients with advanced UCC were randomly assigned to GEMOX (gemcitabine 1000 mg/m 2 , oxaliplatin 100 mg/m 2 on day 1 [D1] … in statistical terms

"WebReview Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic … " - Cisplatin versus carboplatin

Cisplatin versus carboplatin

Randomized Trial of Intravenous Versus Intraperitoneal …

WebApr 10, 2024 · Triple-negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer and constitutes 10–20% of all breast cancer cases. Even though platinum-based drugs such as cisplatin and carboplatin are effective in TNBC patients, their toxicity and development of cancer drug resistance often hamper their clinical use. Hence, novel … WebApr 16, 2024 · All four planned doses of cisplatin or carboplatin were received by 82.5% of the patients in the pembrolizumab-combination group and by 74.3% of those in the placebo-combination group; 76.5% and ...

Did you know?

WebMay 14, 2024 · Ohe Y, Ohashi Y, Kubota K, et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and Vinorelbine plus Cisplatin for advanced non-small-cell lung cancer: Four-arm cooperative study in Japan. Ann Oncol 18: 317-323, 2007 Crossref, Medline, Google Scholar: 13. WebApr 4, 2024 · Carboplatin belongs to a class of medications known as platinum-containing compounds. It works by stopping or slowing the growth of cancer cells. Carboplatin is …

WebHotta K, Matsuo K. Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer. J Thorac Oncol. 2007;2(1):96. 4. Hamdi T, Latta S, Jallad B, Kheir F, Alhosaini MN, Patel A. Cisplatin-induced renal salt wasting syndrome. WebApr 19, 2024 · Adjusted HR (95% CI) of PFS for intraperitoneal (IP) carboplatin vs. intravenous (IV) carboplatin = 0.92 (0.75 – 1.13). Adjusted HR (95% CI) of PFS for IP cisplatin vs. IV carboplatin = 0.97 (0.79 – 1.19). There was no statistically significant difference in PFS between the IV regimen and either of the IP regimens in this subgroup …

WebJun 1, 2016 · Carboplatin ( cis -diammine-cyclobutanedicarboxylato-platinum (II)) was initially believed to have “comparable” therapeutic activity with cisplatin but is associated … WebJun 1, 2016 · In comparison with carboplatin, the use of cisplatin has been more extensively evaluated in the systemic management of endometrial cancer. A recent …

WebCisplatin carries a higher toxicity profile, including nausea, vomiting, neuropathy, renal insufficiency, and alopecia in comparison to carboplatin. When the goal of …

WebThere have been limited data comparing outcomes of carboplatin vs. cisplatin-based CRT, particularly in elderly. Material and methods: From the Surveillance, Epidemiology and End Results-Medicare registry, we identified 1878 patients >65 years of age with unresected stage III NSCLC that received concurrent CRT between 2002 and 2009. j.l. hufford coffee \\u0026 tea coWebMar 30, 2024 · The ubiquitin-proteasome system plays an important role in acquiring resistance to rituximab and chemotherapy agents in B-cell lymphoma. 9, 10 Carfilzomib (CFZ, PR-171) is a potent, tetrapeptide ketoepoxide–based inhibitor specific for the chymotrypsin-like active site of the 20S proteasome. It was first approved for the … j l hufford coffee \\u0026 tea company lafayetteWebJun 18, 2024 · Among chemotherapeutics with potentially lower nephrotoxicity, the inferiority of the carboplatin-Carboplatin, Etoposide, Bleomycin (CEB) versus BEP regimen has been previously demonstrated in randomized trials. [8,9] In the Horwich study, patients received either 4 series of BEP or 4 series of CEB. instation invilliaWebMar 30, 2024 · Rao S, Jones M, Bowman J, Tian C, Spano JP. POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. Front Oncol. 2024 Aug 24;12:935383. doi: 10.3389/fonc.2024.935383. … instatin incWebApr 2, 2012 · Cisplatin is associated with more GI adverse effects, neurotoxicity, and renal function impairment, and its administration requires a prolonged hydration, 5, 6 but carboplatin is associated with more myelosuppression. Although the mechanisms of action are similar, it is unclear whether carboplatin and cisplatin have the same clinical efficacy. instation learning toolWebSelect search scope, currently: articles+ all catalog, articles, website, & more in one search; catalog books, media & more in the Stanford Libraries' collections; articles+ journal articles & other e-resources j l hufford coffee \u0026 tea company lafayetteWebOct 20, 2024 · Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? a randomized phase III comparison of weekly carboplatin and … jlhv consulting ab